Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - dicloxacillin sodium, quantity: 542.52 mg (equivalent: dicloxacillin sodium, qty 500 mg) - capsule - excipient ingredients: silicon dioxide; magnesium stearate; gelatin; titanium dioxide; patent blue v; quinoline yellow - dicloxsig is indicated in the treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia. note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia. bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxsig should not be used in infections due to organisms susceptible to benzylpenicillin. important note: when it is judged necessary that the treatment be initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase resistant penicillin.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - dicloxacillin sodium, quantity: 271.26 mg (equivalent: dicloxacillin, qty 250 mg) - capsule - excipient ingredients: silicon dioxide; magnesium stearate; gelatin; titanium dioxide - dicloxsig is indicated in the treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia. note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia. bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxsig should not be used in infections due to organisms susceptible to benzylpenicillin. important note: when it is judged necessary that the treatment be initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase resistant penicillin.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lansoprazole, quantity: 30 mg - capsule - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; indigo carmine; colloidal anhydrous silica; titanium dioxide; maize starch; purified talc; macrogol 300; sucrose; carmoisine; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - adults:. lanzopran capsules are indicated for. - healing and long-term management of reflux oesophagitis. . - healing and long-term management for patients with duodenal ulcer.. - healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - patients with benign peptic lesions that do not respond to h2-receptor antagonists.. - eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric and adolescent patients i to 17 years of age:. lanzopran capsules are indicated for. - treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - healing of erosive oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole, quantity: 40 mg - capsule, enteric - excipient ingredients: crospovidone; glyceryl monostearate; triethyl citrate; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; purified talc; hyprolose; mannitol; sodium hydroxide; sucrose; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; maize starch - noxicid is indicated for: 1. gastro-oesophageal reflux disease (gord) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (gord) 2. patients requiring nsaid therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. 3. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion 4. in combination with appropriate antibiotics for: - healing of duodenal ulcer associated with helicobacter pylori - eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole, quantity: 20 mg - capsule, enteric - excipient ingredients: glyceryl monostearate; mannitol; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; hyprolose; crospovidone; triethyl citrate; purified talc; sodium hydroxide; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate; maize starch - noxicid is indicated for: 1. gastro-oesophageal reflux disease (gord) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (gord) 2. patients requiring nsaid therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. 3. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion 4. in combination with appropriate antibiotics for: - healing of duodenal ulcer associated with helicobacter pylori - eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - doxepin hydrochloride, quantity: 28.25 mg (equivalent: doxepin, qty 25 mg) - capsule, hard - excipient ingredients: purified talc; sodium starch glycollate; titanium dioxide; gelatin; lactose monohydrate; colloidal anhydrous silica; brilliant blue fcf; erythrosine; sodium lauryl sulfate; magnesium stearate - for the treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - venlafaxine hydrochloride, quantity: 84.86 mg - capsule, modified release - excipient ingredients: hypromellose; magnesium stearate; sodium lauryl sulfate; ammonio methacrylate copolymer; basic butylated methacrylate copolymer; titanium dioxide; iron oxide red; potable water; gelatin - treatment of major depression, including prevention of relapse and recurrence where appropriate; generalised anxiety disorder; social anxiety disorder; and panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - venlafaxine hydrochloride, quantity: 169.71 mg - capsule, modified release - excipient ingredients: magnesium stearate; hypromellose; ammonio methacrylate copolymer; sodium lauryl sulfate; basic butylated methacrylate copolymer; titanium dioxide; indigo carmine; erythrosine; potable water; gelatin - treatment of major depression, including prevention of relapse and recurrence where appropriate; generalised anxiety disorder; social anxiety disorder; and panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - emtricitabine, quantity: 200 mg - capsule, hard - excipient ingredients: crospovidone; povidone; microcrystalline cellulose; magnesium stearate; propylene glycol; purified water; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; potable water; gelatin; sodium lauryl sulfate - emtriva is indicated for the treatment of hiv in combination with other antiretroviral agents in adults and paediatric patients 12 years of age and older, weighing more than 33 kg. evidence to support this claim is based on surrogate markers (plasma hiv rna and cd4 count) in antiretroviral naive individuals and in antiretroviral experienced individuals with virological suppression (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - vorinostat, quantity: 100 mg - capsule - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - zolinza is indicated for the treatment of cutaneous manifestations in patients with cutaneous t-cell lymphoma (ctcl) who have progressive, persistent or recurrent disease subsequent to prior systemic therapies.